APUA is pleased to acknowledge its supporters and partners in “preserving the power of antibiotics®.” APUA programs are funded through multi-year contracts and grants, professional societies and other major foundations, along with unrestricted grants from private corporations.
Project Partners and Collaborators
The Bill and Melinda Gates Foundation
U.S. National Institutes of Health (NIH)
Pan American Health Organization (PAHO)
U.S. Agency for International Development (USAID)
U.S. Department of Agriculture
U.S. Office of Homeland Security
National Biodefense Analysis and Countermeasures Center (NBACC)
World Health Organization (WHO)
Centers for Disease Control and Prevention (CDC)
US Food and Drug Administration (USFDA)
Ministries of Health
PEW Charitable Trusts
APUA Corporate Sponsors
"At Alere Inc., we believe that people all over the world want to be involved in their own healthcare while remaining in their homes and that, when they do so, they have an improved quality of life. Our primary areas of focus are cardiology, infectious disease, women’s health, oncology and toxicology."
"By providing individuals with the tools and services they need to make better decisions at home, under medical supervision, we are able to help them improve their health or delay the progression of an existing chronic problem."
"A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. bioMérieux’s mission is to play a major role in the fight against infectious disease in clinical biology by:
Bayer Healthcare Pharmaceuticals
- providing the entire public health community with reliable integrated solutions
- reinforcing the rapidity and accuracy of medical decisions in a global environment of health care cost control."
"Bayer is an inventor company with a long tradition of research. By applying science to the major global challenges, we deliver innovations that address unmet customer and market needs."
"By working sustainably and accepting our role as a socially and ethically responsible corporate citizen – and by committing to our Bayer values – we create benefits for the communities in which we live."
"Science For A Better Life: this is the promise we all give to our stakeholders."
Preventing the spread of resistant bacteria is a critical step in preventing infections from occurring and helps to preserve the efficacy of existing antibiotics by reducing the amount of antibiotics that have to be used and the likelihood that resistance will develop during therapy.1 Environmental hygiene plays a vital role as part of a horizontal approach to infection prevention and control and is especially important when it comes to resistant pathogens like C. difficile, MRSA and VRE. Building on a century-long legacy in cleaning and disinfecting, Clorox Healthcare offers a wide range of products to help stop the spread of infection in healthcare facilities. From comprehensive surface disinfection, including advanced ultraviolet technology, to skin antisepsis, we are committed to providing efficacious solutions to the healthcare community.
In 2004, a diverse product-development team founded BacterioScan with a single-minded mission — to bring quantum-leap innovation to critical microbial lab â€‹procedures. Subsequently, BacterioScan developed, patented and clinically validated a unique electro-optic technology and instrumentation platform for rapidly detecting and quantifying bacteria in fluids. This family of instruments and disposables provide microbiologists with significant improvement in sensitivity, accuracy, and precision in measurement of bacterial growth, and is opening new applications in the rapid diagnosis of infectious disease, and the precise measurement of antibiotic performance. It promises to revolutionize the treatment of infection by more accurately targeting the right therapy at the right time. The BacterioScan platform of products span both the research and clinical diagnostic markets.
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. - See more at: http://www.cubist.com/about/#sthash.5o9rAq5p.dpuf
Da Volterra is a privately-held biotechnology company, headquartered in Paris, France. The company was created in 2000 by Professor Antoine Andremont whose research is dedicated to understanding the impact of antibiotics on the intestinal flora. He is one of the most renowned thought leaders in the field of antibiotic resistance and a pioneer in conceiving strategies to tackle antibiotic resistance at the root.
Australian Society for Antimicrobials (APUA-Australia)
"ASA is made up of a diverse background of professions interested in the study of antimicrobials including clinical microbiologists and infectious diseases physicians, respiratory and ICU physicians, medical and non-medical microbiologists and scientists, pharmacists, veterinarians, undergraduate and postgraduate students, and industry representatives from pharmaceutical and diagnostic/research biomedical companies."
"Although ASA's membership is primarily based in Australia and New Zealand, it now extends to Asia, North America, Europe and the United Kingdom."
British Society for Antimicrobial Chemotherapy (APUA-United Kingdom)
"An inter-professional organisation with 40 years of experience and achievement in antibiotic education, research and leadership."
"Dedicated to saving lives through appropriate use and development of antibiotics now and in the future."
"Communicates effectively about antibiotics and antibiotic usage via workshops, professional guidelines and its own high impact international journal."
The Health Authority – Abu Dhabi (APUA-United Arab Emirates)
"The Health Authority – Abu Dhabi (HAAD) is the regulative body of the Healthcare Sector in the Emirate of Abu Dhabi and ensures excellence in Healthcare for the community by monitoring the health status of the population.
HAAD defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system.
In addition HAAD shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world – class best practices and performance targets by all healthcare service providers in the Emirate.
HAAD also drives programs to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system in the Emirate of Abu Dhabi."
APUA- South Korea
Since the founding of the APUA-Korea Chapter in 2000, the chapter has been one of APUA’s most active and accomplished. Achievements to date include:
Recognition of APUA-South Korea as an NGO.
Establishment a fruitful collaboration with the Asian Medical Center which coordinates the National Antimicrobial Resistance Surveillance Network.
Establishment of the Center for Antimicrobial Resistance and Microbial Genetics by Chapter Coordinator Dr. Yang Soo Kim at the University of Ulsan.
Collaboration with the Center for Antimicrobial Resistance and Microbial Genetics to complete a research project on the difference in the rates of antimicrobial resistance isolated from healthy people before and after the introduction of the separation of the roles of pharmacists from physicians in July of 2000.
Completion of a brief paper detailing the problem of antibiotic resistance in Korea for the APUA newsletter.
Pro bono legal services provided by Holland & Knight, LLP
Conflict of Interest Policy and Guidelines on Interaction with Commercial Enterprises
Page last updated March 2014